

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 March 2022 (24.03.2022)



(10) International Publication Number
WO 2022/058463 A1

(51) International Patent Classification:

A61K 31/7125 (2006.01) A61P 3/06 (2006.01)
A61K 47/54 (2017.01) C07H 21/04 (2006.01)
A61K 47/56 (2017.01)

(21) International Application Number:

PCT/EP2021/075546

(22) International Filing Date:

16 September 2021 (16.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/079,947 17 September 2020 (17.09.2020) US
63/104,107 22 October 2020 (22.10.2020) US
63/122,199 07 December 2020 (07.12.2020) US
63/140,373 22 January 2021 (22.01.2021) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151 85, Södertälje (SE).

(72) Inventors: **RYDÉN-BERGSTEN, Tina**; AstraZeneca AB, SE-151 85 Södertälje (SE). **REKIC, Dinko**; AstraZeneca AB, SE-151 85 Södertälje (SE). **NILSSON, Catarina**; AstraZeneca AB, SE-151 85 Södertälje (SE).

KNÖCHEL, Jane; AstraZeneca AB, SE-151 85 Södertälje (SE).


(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: PCSK9 INHIBITORS AND METHODS OF TREATMENT USING SAME

FIG. 2



(57) Abstract: The present disclosure provides dosages and methods for treating a disease associated with proprotein convertase subtilisin/kexin type 9 (PCSK9). The present disclosure also provides unit dosages, dosing regimens and methods for treating a disease associated with PCSK9.

WO 2022/058463 A1

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*